AI-generated analysis. Always verify with the original filing.
Ocugen, Inc. announced Q4 and full year 2025 financial results, reporting increased R&D expenses and net losses per share, alongside completing enrollment in the OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa and positive preliminary Phase 2 data for OCU410 in geographic atrophy. The company raised $22.5 million in January 2026 to extend cash runway into Q4 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Report, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Ocugen, Inc. dated March 4, 2026. 99.2 Earnings Release Presentati
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $10.70 | GAAP |
| General and Administrative Expenses | $6.10 | GAAP |
| Net Loss per Common Share | $0.06 | GAAP |